Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nomegestrol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 7/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.67 |
| ▸ | AR | P10275 | 4/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SHBG | P04278 | 2/20 | 0.46 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nomegestrol SCHEMBL139763 | 0.93 | LMNA (0.80) | LMNACYP2C19CYP3A4CYP2C9PGR | |
| Nomegestrol SCHEMBL19760878 | 0.93 | LMNA (0.80) | LMNACYP2C19CYP3A4CYP2C9PGR | |
| Nomegestrol SCHEMBL27486762 | 0.93 | LMNA (0.76) | LMNACYP2C19CYP3A4CYP2C9PGR | |
| Nomegestrol SCHEMBL6415665 | 0.92 | LMNA (0.79) | LMNACYP2C19CYP3A4CYP2C9PGR | |
| Nomegestrol SCHEMBL37518 | 0.91 | LMNA (0.77) | LMNACYP2C19CYP3A4CYP2C9PGR | |
| SCHEMBL9322389 | 0.87 | LMNA (0.82) | LMNACYP2C19CYP3A4CYP2C9PGR | |
| SCHEMBL141181 | 0.82 | CYP2C19 (0.64) | LMNACYP2C19CYP3A4CYP2C9PGR | |
| Acetic Acid SCHEMBL282894 | 0.81 | CYP2C19 (0.62) | LMNACYP2C19CYP3A4CYP2C9PGR | |
| Nomegestrol Acetate SCHEMBL8817628 | 0.80 | PGR (1.00) | LMNACYP2C19CYP3A4CYP2C9PGR | |
| Nomegestrol Acetate SCHEMBL37517 | 0.80 | PGR (1.00) | LMNACYP2C19CYP3A4CYP2C9PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1407898-A | Novel topical oestroprogestational compositions with systemic effect | THERAMEX (MC) | 2003-04-02 | — | — | CN | claimed |
| US-20080227763-A1 | Administering hormone replacement therapy by applying a gel of Nomegestrol or Nomegestrol acetate to the skin; restoring genital bleeding in menopausal women | LABORATOIRE THERAMEX | 2008-09-18 | — | — | US | disclosed |
| US-7030104-B2 | Topical oestroprogestational compositions with a systemic effect | LABORATOIRE THERAMEX (MC) | 2006-04-18 | — | — | US | disclosed |
| CN-1161102-C | Systemic topical hormone compositions | ̩��÷˹ʵ���� | 2004-08-11 | — | — | CN | disclosed |
| US-20030181430-A1 | Novel topical oestroprogestational compositions with a systemic effect | LABORATOIRE THERAMEX (MC) | 2003-09-25 | — | — | US | disclosed |
| CN-1407898-A | Novel topical oestroprogestational compositions with systemic effect | THERAMEX (MC) | 2003-04-02 | — | — | CN | disclosed |
| CN-1301146-A | Topical hormonal composition with systemic effect | THERAMEX (MC) | 2001-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181430-A1 | Novel topical oestroprogestational compositions with a systemic effect | CYP19A1, PGR, SHBG | PGR 2/4885LMNA 1665/4885CYP2C19 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.